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Abstract 
Introduction: Cetuximab is a mouse-human chimeric antibody directed against 
the Epidermal Growth Factor Receptor (EGFR). EGFR-dependent signaling plays 
a crucial role in epithelial cancer biology, so several anti-EGFR agents have been 
developed. Cetuximab was the earliest and after about two decades it gained a 
place in the management of advanced colorectal and head and neck cancers, 
whereas it has had a tough time in Non Small Cell Lung Cancer (NSCLC), where 
despite statistically significant phase III trials, the clinical benefit observed was 
marginal and insufficient to grant cetuximab approval from regulatory bodies 
and a place in routine clinical practice.  
Areas covered: we have retrieved literature on the role of Cetuximab in NSCLC, 
including preclinical studies and clinical trials, focusing on recent findings. 
Expert opinion: Cetuximab currently has no role in NSCLC treatment outside of 
research settings. We summarize the historical developement of Cetuximab 
research and argue that failure to identify a predictive biomarker has so far 
hampered its chances to enter routine practice. We identify crucial issues that 
should be addressed in future research, most importantly the role of EGFR 
amplification as predictive biomarker. 
Overview 
Non Small Cell Lung Cancer (NSCLC) is among the most frequent and deadliest 
neoplasms in western world. According to SEER estimates, incidence for lung 
cancer in 2016 is around 225.000 total cases in the USA, ~13% of all new cases. 
NSCLC accounts for 84% cases, with adenocarcinoma and squamous cell 
histologies accounting for 88% of all NSCLC (1). In more than 50% of the cases 
NSCLC presents with locally advanced or metastatic disease, where prognosis 
remains dismal. For stage IIIA NSCLC, 5 year survival is about 14%, but it drops 
to less than 5% for IIIB and metastatic (2). When Cetuximab initiated its clinical 
developement in early 2000s, no targeted agent was available for NSCLC, and 
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research was focused on identifying the best platinum-based doublet, which 
remain the cornerstone of therapy for metastatic disease to date, with the 
addition of radiotherapy for locally advanced disease. No real consensus has 
been reached for the optimal platinum companion, with taxanes, pemetrexed 
and vinca alkaloids as first choices (3–5). Anti-angiogenic therapy with 
Bevacizumab or Ramucirumab can add a moderate advantage at the price of 
significant toxicity and can be added in selected patients (3,5–7). Targeted 
therapy has gained an important role in NSCLC, with the approval of two main 
classes of drugs. Patients with translocations involving ALK and ROS, accounting 
for < 5% of all NSCLC, can now be treated with oral inhibitors crizotinib, ceritinib 
or alectinib as monotherapy (3,5,8–10). Patients with EGFR mutations, 
accounting for a larger share (up to 18%, with wide variations across nations 
(11)) are treated with EGFR tyrosine kinase inhibitors (TKI) erlotinib, gefitinib 
or the 2nd generation afatinib in the first line. All these compounds provided 
advantages in progression-free-survival (PFS) by not overall survival (OS) 
compared to standard chemotherapy (3,5,12). Despite the variety of agents 
approved, the vast majority of locally advanced or metastatic tumors relapse and 
response rates in second line and more are still extremely low, with no agent 
able to provide significant improvements in survival over supportive care. Given 
its high mortality and incidence, there are ample margins of improvement. The 
arena of new drugs has widened significantly in recent years. Probably the most 
dramatic changes have been brought about by the introduction of immune 
checkpoint inhibitors, initially only in second line (nivolumab, pembrolizumab 
and atezolizumab) and more recently in the first line (pembrolizumab) (13–15).  
New agents for targeted therapy are currently in advanced developement or 
have recently been FDA-approved, including new targeted therapies against 
EGFR (dacomitinib, AZD9291, rociletinib, osimertinib and others) or other 
signaling pathways (MEK inhibitors like selumetinib, MET inhibitors like 
tivantinib and cabozantinib and others). Cetuximab is also not the only anti-
EGFR antibody in developement. Earlier competitors like Panitumumab and 
Matuzumab failed in phase 2 clinical trials (16,17); Necitumumab had better 
success, with a recent FDA approval for the treatment of squamous cell lung 
cancer based on the results of the SQUIRE trial (18). 
Introduction to the compound 
Cetuximab began its clinical developement in the late 90s and was among the 
first targeted therapies to be developed in the context of NSCLC. The impetus 
was the observation, a decade earlier, that many lung cancer cells express EGFR 
at high levels and are dependent on its signaling for growth (19–22). 
Chemistry 
Cetuximab was obtained by chimerization with the human IgG1 constant region 
of the murine fraction variable regions from myeloma cell line 225, producing an 
antibody that blocks the ligand-binding site of the EGFR (20–25). It has an 
approximate molecular weight of 152 kDa. 
Pharmacodynamics 
Cetuximab has high affinity to the EGFR, surprisingly higher than the original 
murine antibody 225 (23,24,26). It inhibits ligand binding and ligand-mediated 
receptor phosphorylation, in particular on Mitogen-Activated Kinases (MAPK). In 
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addition, there is also evidence suggesting that cetuximab promotes receptor 
internalisation, reducing the number of receptors available for interaction with 
the ligand (26,27). Finally, there is in vitro evidence for antibody-dependent 
cellular cytotoxicity but no complement-mediated lysis (24). Cetuximab 
treatment enhances direct cytotoxicity from radio and chemotherapy(28). 
Combination with chemotherapy it was recently found to induce so-called 
immunogenic cell death (29). 
Pharmacokinetics and metabolism 
After 2-hour infusion of 250 and 400 mg/m2, maximum concentrations are 
reached 1hr later at 158.1 and 205 ug/mL and the elimination half lives are 71 
and 75.1 hours, respectively. The volume of distribution is dose-independent and 
approximated the vascular space of 2 to 3 L/m2 (30). At antibody doses in the 
range of 200 to 400 mg/m2, systemic clearance is saturated (30,31). The PK 
appeared to be nonlinear in all settings analysed (30–32). Concurrent 
administration of chemotherapy or radiotherapy did not alter cetuximab PK (31–
33). Subsequent studies did not identify patient-associated variables (age, 
gender, body weigh, race, etc) associated with different PK and requiring dose 
adjustments (34). 
Clinical efficacy 
Early phase I studies 
Two phase 1 studies established dosing for cetuximab (31,32). The first, by 
Baselga et al, was in fact a combination of 3 trials in which cetuximab was 
explored as a single dose and weekly multiple doses with or without cisplatin. 
Doses ranged from 5 to 400 mg/m2, on a total of 52 patients. Overall, the 
frequency of grade 3 or higher cetuximab-related events was 1.6%. Disease 
stabilizations were observed in all studies. The study with cisplatin was limited 
to head and neck or non–small-cell lung cancer; 69% patients treated with 
antibody doses ≥ 50 mg/m2 had completed 12 weeks of therapy as planned, and 
2 partial responses were observed (31). In the second study, Cetuximab was 
explored at doses up to 500 mg/m2 in combination with radiotherapy in 
patients with advanced head and neck squamous cell carcinoma. Most toxicities 
were associated with radiotherapy but one patient experienced grade 3 skin 
toxicity outside of the irradiation field at the highest dose of 500 mg/m2, which 
suggested the adoption of a lower dose  for subsequent studies (32). 
All patients achieved an objective response (13 complete, 2 partial). On the basis 
of these data, the recommended dose for subsequent studies was set at a loading 
dose of 400 to 500 mg/m2 and a maintenance weekly dose of 250 mg/m2. 
Clinical developement in combination with radiotherapy for stage IIIA-IIIB NSCLC 
 
Six phase II trials (summarized in table 1) have been conducted testing 
cetuximab in combination with concurrent radiotherapy with or without 
chemotherapy in the setting of stage III NSCLC (35–40). 
Earlier single-arm studies on the addition of cetuximab to chemoradiation were 
promising but fairly small. However, subsequent randomized trials failed to 
show superiority of cetuximab addition. In the CALGB 30407 trial, 101 patients 
were randomized to concurrent radiochemotherapy (Pemetrexed + Carboplatin 
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and radiotherapy (60 Gy) with or without Cetuximab. No significant difference 
was demonsrated between the two arms in terms of failure-free survival (12.3 vs 
12.6 months) and OS (25.2 vs 21.2) (35). Another similarly sized randomized 
study, where 102 patients were randomized to receiving or not cetuximab in 
combination with cisplatin and radiotherapy (66Gy), also showed no benefit 
(40). More recently, cetuximab was tested as addition to cisplatin and vinorelbin 
and concurrent individualized, isotoxic accelerated radiotherapy in a single-arm 
phase 1 trial (41). Results were in line with previous studies, with a median OS of 
21.0 months (95% CI 19.0–22.8 months). The final word on the issue was spelled 
out by the RTOG 0617 trial, the largest to date. Two hypotheses were tested at 
the same time: whether RT dose intensification to 74 Gy was superior to 
standard 60 Gy and whether addition of cetuximab to the carboplatin and 
paclitaxel backbone was superior. Recruitment for the RT intensification 
hypothesis was terminated earlier due to futility but recruitment for cetuximab 
met its accrual endpoint and 465 patients wer available for analysis (42). 
Confirming the results of the earlier phase 2 trials, no OS improvement was 
observed with cetuximab (25·0 months [95% CI 20·2–30·5] vs 24·0 months 
[19·8–28·6]; two-sided p=0·58; HR 0·94 [95% CI 0·74–1·19]).  
An alternative approach that deserves consideration, so far tested only in 2 small 
nonrandomized studies, is the use of cetuximab alone with radiotherapy, in 
patients unfit to receive chemoradiotherapy. Jatoi et al administered cetuximab 
concomitant to 60 Gy RT (39), whereas Jensen et al administered cetuximab 
concomitant to 66 Gy IMRT and for subsequent 13 weeks (38). Median OS 
were 15.1 and 19.6 months respectively, which favorably compares to historical 
controls of similar populations treated with radiotherapy alone (43). If this 
approach resists the test of randomized trials, it may have some benefit in this 
difficult to treat population. 
Clinical developement for stage IIIB-IV  
Phase II studies 
The first trials specifically investigating activity of cetuximab in the context of 
NSCLC were two small (n=31-35) phase I/II trials, in combination with either 
paclitaxel/carboplatin (44) or gemcitabine/carboplatin (45) in the first line 
stage IV setting. Response rates of 26% and 29% and median OS of 11.0 and 10.2 
months appeared promising. The Lung Cancer Cetuximab Study (LUCAS) was the 
first trial testing cetuximab in a randomized fashion, coupling it to the regimen 
that would later be tested for its registration study (33). Patients were 
randomized to receive cisplatin/vinorelbine with or without cetuximab, 
administered weekly at 250 mg/m2 after a loading dose of 400 mg/m2 (a 
schedule that has remained the standard in most studies), in 3-week cycles for a 
maximum of 8 cycles. The study was conducted on 86 patients without prior 
sample size calculation; these results appeared again moderately promising, 
with better  response rates (33% vs 28%), median PFS (5.0 vs 4.6, HR = 0.71, 
95% CI 0.4–1.2) and median OS (8.3 vs 7.3 months, HR=0.71, 95% CI 0.5–1.1). 
However, unsurprisingly, no efficacy parameter was statistically significant.  
An additional randomized phase II study on 131 patients (BMS100) tested the 
addition of cetuximab to gemcitabine + cisplatin or carboplatin. Again, there 
were signs of moderate efficacy for the addition of cetuximab, with better 
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response rate (27.7%, 95%CI 17.3 - 40.2 vs 18.2%, 95% CI 9.8 - 29.6), median 
PFS (5.09 months, 95%CI 4.17 - 5.98 vs 4.21 months, 95%CI 3.81 - 5.49) and OS 
(11.99 months, 95%CI 8.80 - 15.18 vs 9.26 months, 95%CI 7.43 - 11.79) (46).  
A more recent, single arm study explored combining cetuximab to cisplatin and 
pemetrexed for 4-6 cycles, followed by maintenance with cetuximab and 
pemetrexed until progression or unacceptable toxicity. The study yielded slight 
improvements over past combinations in terms of ORR (38.5%) and PFS (5.8 
months) and similar OS (11.3 months) (47). 
A further improvement was observed in the SWOG S0536 single-arm phase II 
study on 110 patients, in which both bevacizumab and cetuximab were added to 
carboplatin and paclitaxel for 6 cycles, with both antibodies kept for 
maintenance until progression. ORR was 56%, PFS 7 months (95% CI: 6–8 
months) and median OS was 15 months (95% CI: 11–21 months); toxicity profile 
was deemed acceptable, although there were 4 treatment-related deaths, 2 of 
which due to pulmonary hemorrhage, a well-known bevacizumab-related 
toxicity (48). This study was the basis for designing the ongoing phase III SWOG 
S0819 trial testing cetuximab plus carboplatin and paclitaxel, with or without 
bevacizumab (49). 
Cetuximab was also studied as a single-agent in heavily pretreated NSCLC, 
obtaining a response rate of 4.5%, in line with that of other antiblastics and EGFR 
inhibitors tested in the same setting (50).  
Phase III studies 
The pivotal phase III trial leading to FDA approval in NSCLC was FLEX (51). 1125 
patients were randomized to receiving Cisplatin and Vinorelbin plus or minus 
Cetuximab (no placebo, open label); cetuximab was continued until progression 
or unacceptable toxicity. Importantly, patients were required to have IHC-
demonstrated EGFR expression, but the cutoff chosen for positivity was very low 
(at least one postive tumor cell). The study showed a small but statistically 
significant OS improvement (1.2 months, 11.3 vs 10.1 months, HR=0.871, 
p=0.044) at the price of worse toxicity profile (higher febrile neutropenia, rash, 
diarrhea and infusion-related reactions). The study spurred controversy in its 
aftermath. Despite the trial meeting its primary endpoint (OS), neither FDA nor 
EMA granted approval for NSCLC, given the marginal benefit and the use of a 
suboptimal comparator arm. Concerns grew as a subsequent trial (BMS099 (52)) 
in which cetuximab failed to demonstrate significant benefit when added to a 
possibly more effective chemotherapy. Chemotherapy-naive (n=676) patients 
were randomized to receiving chemotherapy (carboplatin + a taxane at 
physician's choice) with vs without cetuximab. PFS, the primary endpoint, did 
not differ (4.4 vs 4.24 months, HR=0.902, 95% CI 0.761- 1.069, p=0.24); OS 
showed a trend favouring the cetuximab arm but the trial was not powerful 
enough to demonstrate such small OS improvement (9.7 vs 8.4 months, 
HR=0.890 95% CI 0.754- 1.051; p=0.17). Metanalyses pooling data from all four 
randomized trials described above (LUCAS, BMS100, BMS099 and FLEX) 
confirmed the modest but statistically significant advantage in OS of adding 
cetuximab to chemotherapy (53–55). Randomized studies are summarized in 
table 2. 
There is some evidence supporting the use of cetuximab maintenance in 
monotherapy in patients free of disease after first line therapy with platinum-
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based CT. This trial (NEXT) was designed to test weekly vs bi-weekly cetuximab 
administration but recruitment was halted pematurely because of the EMA 
negative ruling on cetuximab (56). Results were nevertheless published and 
showed good OS of 12.6 months , comparable to other studies in the same 
setting, with no significant differences between the two adinistration schedules. 
Cetuximab was also tested in the second line setting after failure of platinum-
based therapy, in combination with docetaxel or pemetrexed, but no significant 
improvement was observed (57). 
The search for predictive biomarkers 
Much research has attempted to identify genetic biomarkers predictive of 
response to anti-EGFR antibodies. These efforts have generated practice-
changing results in colorectal cancer, but in the context of NSCLC things have 
been more difficult. Retrospective analyses of the FLEX and BMS099 trials 
showed no evidence that K-ras mutations or PTEN deletions mediate resistance 
to cetuximab (58–60). Also, the presence of an EGFR mutation is not predictive, 
as summarized in a Cochrane review (12). Instead, mounting evidence points to 
EGFR gene amplification and/or overexpression as a good predictive biomarker. 
In FLEX, cases with an elevated immunohistochemistry score (31% of enrolled 
patients) had better survival when treated with the addition of cetuximab 
(median survival of 12.0 vs 9.6 months, HR 0∙73, 95% CI 0∙58–0∙93; p=0∙011). A 
retrospective analysis of 2 phase II trials suggested better but marginally 
significant benefits from FISH-evaluated high EGFR copy number (48,61). 
Preliminary results from the SWOG S0819 testing cetuximab with bevacizumab 
and chemotherapy confirmed this association (62). In apparent contrast with 
these findings, EGFR amplification showed no predictive power in FLEX (58). 
With a more careful look at the data, survival and response was possibly 
superior in FISH-positive patients treated with cetuximab (11.6 vs 9.9 months), 
but the number of samples analysed (25% of the original 1125) was certainly too 
small to confer sufficient power (p=0.44). Interestingly, in FLEX the percentage 
of patients FISH-positive is similar to those scored as high by IHC (37% vs 31%), 
suggesting that the two tests may infact identify a largely overlappig population. 
This is confirmed by analysing data from The Cancer Genome Atlas, where it is 
clearly visible that EGFR amplification is associated with significant increase in 
EGFR mRNA expression (figure 1, data retrieved from cBioportal (63) on 
provisional lung adenocarcinoma and provisional squamous lung cancer on 14 
october 2016) 
New combinations with biological agents 
Based on the laboratory finding that NSCLC with acquired resistance to erlotinib 
and gefitinib remain dependent on EGFR for growth (64,65), several labs began 
testing combinations of alternative EGFR inhibitors for use after failure of TKI 
therapy. The combination of cetuximab and afatinib, a second generation TKI, 
proved effective on mouse models (66). This led to the design of a phase 1b trial 
with a dose finding phase and two subsequent expansion phases exploring  
concurrent afatinib + cetuximab or afatinib +cetuximab initiated  after failure of 
afatinib alone (67). In departure from previous schedules, cetuximab was 
administered as 500 mg/m2 every 2 weeks. 201 patients progressing to TKI for 
an EGFR-mutated NSCLC were enrolled, of which 126 were treated at the MTD of 
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both drugs. ORR was 29%, a good improvement from the 7-8% observed in trials 
with afatinib or cetuximab alone on similar populations (68). Interestingly, 
cetuximab seems to also synergize with a novel allosteric EGFR inhibitor 
(EAI045) and the combination potently inhibits growth in mouse models of lung 
cancer driven by EGFR mutants resistant to all EGFR TKIs (69). 
Other combinations with biologicals, such as with cilengitide (an integrin 
inhibitor)(70) or with cixutuxumab (IGF1R inhibitor) (71) did not give good 
results. 
Safety and tolerability 
The most characteristic toxicity associated with cetuximab is an acne-like rash, 
tha develops in up to 90% of patients and is dose-related (72,73). It usually 
manifests within the first 2 weeks of therapy and is characterized by a 
maculopapular eruption localized to face and trunk, areas with high density of 
seborrheic glands. The rash is classified as G1-G2 in most cases, with a much 
smaller incidence of G3 or more events. However, since it is  chronic and 
disfigurating, it is often a reason for treatment discontinuation. Also, there is a 
clear subjective bias for evaluating cetuximab rash severity, with oncologists 
systematically giving lower scores compared to dermatologists (74). The 
severity of rash is potentially increased when cetuximab is co-administered with 
radiotherapy (75), given the role of EGFR in the repair of skin lesions. However, 
the incidence of grade ≥3 was similar in the phase 3 trials with chemo alone or 
chemoradiotherapy (10% in FLEX, 9% in RTOG 0617) (42,51). Combination of 
cetuximab with other EGFR inhibitors does not lead to increased severity of 
cutaneous toxicity (76). The rash may complicate with bacterial superinfections. 
Other skin toxicities are also common but rarely high grade with cetuximab, 
including xerosis, paronychia, hair growth abnormalities including alopecia and 
trichomegaly of the eyelashes/hypertrichosis of the face, and telangiectasias 
(72,77). Topical or oral antibiotics (macrolides, clindamycin or tetracyclines), 
topical corticosteroids and vitamin K creams can be employed to control severity 
(72). 
Other common toxicities are fatigue, fever, nausea, diarrhea, which are probably 
unrelated to dose or number of cycles administered (73). Less common are 
electrolyte imbalances, particularly hypomagnesemia (17), which may occur 
weeks or even months after cetuximab interruption and for which periodic 
monitoring during treatment and up to at least 8 weeks after treatment end is 
advised (73). In the two trials in which Quality of Life (QoL) measurements were 
reported (51,52), no statistically significant differences were observed. Toxicity 
data as collected for the Cochrane metanaysis (55) is summarized in table 3. 
Expert opinion 
Cetuximab is currently not approved for NSCLC treatment in Europe nor in the 
USA. It remained on ASCO and NCCN guidelines for some years but it was 
removed from both documents in 2016 (3,5). Despite statistically significant 
results from the registration studies, routine cetuximab use failed to gain 
consensus because of its high cost-benefit ratio: the price in both monetary and 
toxicity terms is cosidered too high for a marginal gain of 1.2 months in OS 
(78,79). Thus, interest in this molecule has waned and remains confined to 
research setting. We think that the main reason for its failure lies in the inability 
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to identify a clear predictive biomarker early during drug developement. The 
current emphasis on precision oncology based on genetic markers may carve a 
niche for cetuximab resurrection. Cetuximab-responsive NSCLC do exist out 
there, but they are likely to be a small and defined fraction of all NSCLC. Had such 
biomarker been identified before clinical developement, we might have seen a 
Herceptin-like story. In fact, we think that most efforts should be focused on 
consolidating the role of EGFR amplification as a predictive biomarker. Current 
evidence from the SWOG S0819 is still preliminary but deserves to be invested 
on. 
A second possible niche is in the treatment of metastatic EGFR-mutated NSCLC in 
combination with new generation TKIs, hoping to slow down or temporarily 
revert the acquisition of genetic resistance. Recent data from preclinical and 
phase 1b studies (67,69) is promising. This strategy is currently being explored 
in randomized trials, on TKI-naïve patients (NCT02438722, NCT02716311) and 
on patients with acquired resistance (NCT00716456). 
Lastly, in the context of locally advanced NSCLC, further research should 
investigate its role as adjunct to radiotherapy in patients unfit to undergo 
chemoradiation. This approach has gained some following in the context of Head 
and Neck cancer (80), but in NSCLC the evidence in favour of this approach is so 
far represented only by small nonrandomized studies (38,39). The impact on 
quality of life, if demonstrated noninferior to chemoradiation, might be high. 
 
Conclusion 
Cetuximab demonstrated improved efficacy over standard therapy in both 
locally advanced and metastatic NSCLC, but the absolute survival gain in 
unselected populations is very small and so far deemed unjustifiable in light of 
the chronic toxicity. Further research is required to identify highly selected 
patient subsets where cetuximab may still have a beneficial impact   
 
Article highlights 
• Cetuximab provides statistically significant but clinically marginal OS gain 
in unselected NSCLC 
• It is currently not a viable therapeutic option in routine practice 
• EGFR amplification is a likely predictive biomarker 
• Combining cetuximab to EGFR TKIs may be effective in cases of primary 
or acquired TKI resistance 
• Its role as adjunct to radiotherapy in stage IIIA patients unfit for 
chemoradiation should be explored  
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Table 1: Trials combining cetuximab with (chemo)radiation 
 
  Year study 
type 
n Pts Patient 
stage 
Chemotherapy 
regimen 
RT 
(Gy) 
OS 
(mon
ths) 
2-
yr
s 
O
S 
N0422, 
Jatoi et al 
2010 phase 2, 
single 
arm 
58 IIIA 59%, 
IIIB 49% 
Concurrent 
Cetuximab 
60 15.1 22
% 
NEAR, 
Jensen et 
al 
2011 phase 2, 
single 
arm 
30 II 7%, 
IIIA  57%, 
IIIB 37% 
Concurrent 
Cetuximab 
followed by 
maintenance 
Cetuximab 
66 19.5 35
% 
SATELLIT
E, 
Hallqvist et 
al 
2011 phase II, 
single 
arm 
71 IIIA 37%, 
IIIB 63% 
Induction 
Docetaxel and 
CDDP followed by 
concurrent 
Cetuximab 
68 17 37
% 
RTOG 
0324, 
Blumensch
ein et al 
2011 phase II, 
single 
arm 
87 IIIA 46%, 
IIIB 54% 
Concurrent  
CBDCA, 
Paclitaxel and 
Cetuximab 
followed by 
Consolidation 
CBDCA and 
Paclitaxel 
65 22.7 49
% 
 CALGB 
30407, 
Govindan 
et al 
2011 phase II, 
randomi
zed 
101 IIIA 55%, 
IIIB 42% 
Concurrent 
CBDCA and 
Pemetrexed 
followed by 
consolidation 
Pemetrexed 
70 21.2  
Concurrent 
CBDCA and 
Pemetrexed + 
Cetuximab 
followed by 
consolidation 
Pemetrexed 
25.2  
van den 
Heuvel et 
al 
2014 phase II, 
randomi
zed 
102 II 8%, 
IIIA 51%, 
IIIB 41% 
Concurrent 
Cisplatin  
66 n.a. 
(HR
=1) 
58
% 
     Concurrent 
Cisplatin + 
Cetuximab 
  62
% 
RTOG 
0617, 
Bradley et 
al 
2015 phase 
III, 
randomi
zed 
465 IIIA 65%, 
IIIB 35% 
Concurrent and 
consolidation 
CBDCA and 
Paclitaxel  
60 or 
74 
24 
(19.8
-
28.6) 
50
.1
0
% 
    Concurrent and 
consolidation 
CBDCA and 
Paclitaxel + 
cetuximab 
25 
(20.2
-
3056
) 
52
.3
0
% 
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Table 2. Randomized trials in stage IIIB-IV NSCLC 
 
Reference Year study 
type 
Patient 
number 
Therapy regimen OS 
months 
(95% 
CI) 
PFS 
months 
(95% 
CI) 
ORR 
FLEX, 
Pirker et 
al  
2009 phase 
3 
1125 Cetuximab+cisplatin+vinorelbine 10.5 
(9.2-
12.0) 
4.8 
(4.2-
5.3) 
36% 
cisplatin+vinorelbine 9.1 
(8.2-
10.1) 
4.8 
(4.4-
5.3) 
29% 
BMS 099,   
  
2010 phase 
3 
676 Cetuximab+carboplatin+taxane 9.69 
(8.28-
11.5) 
4.4 
(4.11-
5.06) 
25.70% 
carboplatin+taxane 8.38 
(7.33-
9.62) 
4.24 
(3.94-
4.63) 
17.20% 
BMS 100, 
Butts et al  
  
2007 phase 
2 
130 Cetuximab+platinum+gemcitabine 11.99 
(8.8-
15.18) 
5.09 
(4.17-
5.98) 
27.70% 
platinum+gemcitabine 9.26 
(7.43-
11.79) 
4.21 
(3.81-
5.49) 
18.20% 
Lung 
Cancer 
Cetuximab 
Study, 
Rosell et 
al 
2008 phase 
2 
86 Cetuximab+cisplatin+vinorelbine 8.3 
(6.1-
9.9) 
5 (4.5-
5.8) 
35% 
cisplatin+vinorelbine 7.3 
(5.6-
9.5) 
4.6 
(2.5-
6.0) 
28% 
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Table 3: Toxicity (as reported in Yang et al 2014, Cochrane Review) 
 
Cetuximab+Chemo Chemo alone Relative Risk 95% CI 
acneiform rash 11.2 0.3 37.37 
10.66-
130.95 
hypomagnesemia 5.3 0.8 6.57 1.13-38.12 
infusion reaction 3.9 1.1 3.5 1.76-6.94 
diarrhea 4.8 2.3 2.1 1.26-3.48 
hypokalemia 6.3 3.6 1.74 1.02-2.99 
febrile 
neutropenia 10.6 7.6 1.4 1.1-1.77 
leukopenia 58.1 42.7 1.36 1.17-1.58 
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Figure legend 
 
Figure 1: relationship between EGFR expression, copy number and point 
mutations. Data obtained for provisional Lung Adenocarcinoma (left) and 
provisional Lung Squamous Carcinoma from the TCGA through cBioPortal 
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